The Contraceptive Company That’s Actually Printing Money

Yes. They Sell Condoms. And They’re Killing It.

Let’s address the elephant in the room immediately: Cupid Limited manufactures condoms. Male condoms, female condoms, lubricants, and In Vitro Diagnostic kits. It’s been doing this since 1993. For three decades, this company has been quietly operating in an industry where nobody’s proud, yet everybody participates.

The awkwardness is yours, not theirs. Cupid has WHO/UNFPA prequalification — meaning they supply contraceptives to 125+ countries and are literally one of the few companies globally certified to serve the United Nations. This isn’t a bedroom story. This is a public health narrative in a portfolio disguise.

In Q3 FY26, Cupid delivered exactly what management promised: the strongest quarter in its history. Q3 is always the strongest season (higher seasonal demand), but this year it was extraordinary. Revenue doubled. PAT nearly tripled. Order book hit ₹80 crore. And the management is sitting there casually announcing they’ll exceed ₹335 crore revenue guidance by a meaningful margin, with net profit expected to cross ₹100 crore for FY26.

The interesting part? This isn’t a one-trick pony anymore. While the B2B export business — condoms for global tenders — remains the cash engine, Cupid is now scaling a domestic FMCG business (personal care, deodorants, talcum powders), diagnostics kits are becoming material, and they’re even investing ₹331.53 crore in a retail chain to accelerate distribution. Diversification through acquisition. Bold play for a condom company.

Three Engines Running. Two Are On Fire. One’s Warming Up.

Cupid operates three distinct business verticals, each with different economics and growth trajectories.

Engine 1: Export B2B (The Cash Cow) — 90%+ of historical revenues come from exporting contraceptives to global health programs. WHO prequalification for both male and female condoms. UNFPA contracts. Multi-year tenders from governments in South Africa, Brazil, Tanzania. This is government procurement — competitive, regulated, but predictable. South Africa alone just allocated them ₹115 crore over 5 years (59% of their female condom allocation for that country). The margins here are healthy but compressed by bulk pricing. However, once you win a tender, the repeat orders are guaranteed.

Engine 2: FMCG (The Growth Story) — Launched domestic branded products: Cupid condoms, personal lubricants, deodorants, talcum powders, face wash, body oils, even menstrual cups. Currently available across 1.50 lakh+ retail outlets. Margin profile here is significantly higher than B2B (FMCG margins typically 30%+ vs wholesale 15–20%). The catch: it’s early stage. FY25 onwards. Requires distribution investment. Just invested ₹331.53 crore into Baazar Style (a retail chain) to accelerate last-mile reach. Management expects ₹150 crore incremental revenue from this partnership in FY27 alone, scaling to ₹500 crore by year 3.

Engine 3: Diagnostics IVD (The Dark Horse) — 15 rapid diagnostic kits in production: HIV, Syphilis, Pregnancy, Hepatitis B, etc. Just received EU IVDR CE certification in January 2026. Currently supplies 120+ ESIC hospitals. Capacity expanding from 1.5 lakh kits/day to 4 lakh kits/day by end-2026. Addressable market: $1.7–6.1 billion annually across their target categories. This is a play that’s 4–5 years out, but the TAM is enormous.

Q3 FY26: The Numbers That Made Everyone Uncomfortable